Plexus Ventures Assists Fujifilm Kyowa Kirin Biologics in Partnering with Mylan of Humira® Biosimilar

Apr 24, 2018

Tokyo, Japan – Plexus Ventures is pleased to announce the successful conclusion of an out-licensing project of its client Fujifilm Kyowa Kirin Biologics Co., Ltd. Plexus Ventures provided professional services to Fujifilm Kyowa Kirin Biologics to partner the European rights for FKB327, a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics, with Mylan N.V.

“The opportunity to represent Fujifilm Kyowa Kirin Biologics in the partnering of their lead compound, whose Marketing Authorization Application is currently under review by the European Medicines Agency, is a great honor,” said Richard Brown, General Partner and Head, Tokyo Office of Plexus Ventures. “The high-quality development and manufacturing of FKB327 and the excellent reputation of Fujifilm Kyowa Kirin Biologics and its parent companies, FUJIFILM Corporation and Kyowa Hakko Kirin Co., Ltd., distinguishes FKB327 from other adalimumab biosimilars under development.”

President and CEO of Fujifilm Kyowa Kirin Biologics, Dr. Yoshifumi Torii, remarked, “We are very pleased with the strong and knowledgeable support of Plexus Ventures in all phases of the process leading to this important agreement with Mylan. Plexus Ventures’ broad industry network allowed us to select the optimal partner for commercializing FKB327 in Europe.”

Details regarding the transaction are provided in the press release of Fujifilm Kyowa Kirin Biologics: []

About Plexus Ventures

Plexus Ventures has earned the title Business Builders in Healthcare over nearly three decades as a leading corporate and business development consultancy for healthcare industry companies. Plexus assists clients of all sizes and capabilities to achieve their strategic business development objectives. Plexus industry professionals are conveniently located in the United States, Europe and Asia-Pacific markets, enabling Plexus to benefit its clients with both local knowledge and global reach.



Celon Pharma enters agreement with Zydus Lifesciences Ltd.

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Celon Pharma. Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This transaction is an ideal match which...